CY2353B1 - Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents. - Google Patents

Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents.

Info

Publication number
CY2353B1
CY2353B1 CY0300007A CY0300007A CY2353B1 CY 2353 B1 CY2353 B1 CY 2353B1 CY 0300007 A CY0300007 A CY 0300007A CY 0300007 A CY0300007 A CY 0300007A CY 2353 B1 CY2353 B1 CY 2353B1
Authority
CY
Cyprus
Prior art keywords
sugar
substituted
hypocholesterolemic agents
azetidinones useful
azetidinones
Prior art date
Application number
CY0300007A
Other languages
English (en)
Inventor
Nathan P Yumibe
Kevin B Alton
Van Margaret Heek
Harry R Davis
Wayne D Vaccaro
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26677904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2353(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CY2353B1 publication Critical patent/CY2353B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY0300007A 1995-10-31 2003-01-29 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents. CY2353B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US818595P 1995-10-31 1995-10-31
US57084795A 1995-12-12 1995-12-12

Publications (1)

Publication Number Publication Date
CY2353B1 true CY2353B1 (en) 2004-06-04

Family

ID=26677904

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0300007A CY2353B1 (en) 1995-10-31 2003-01-29 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents.

Country Status (28)

Country Link
EP (1) EP0877750B1 (de)
JP (2) JP3385031B2 (de)
KR (1) KR100311554B1 (de)
CN (1) CN1103780C (de)
AR (1) AR004701A1 (de)
AT (1) ATE219495T1 (de)
AU (1) AU712158B2 (de)
BR (2) BR9611401B1 (de)
CA (1) CA2235943C (de)
CY (1) CY2353B1 (de)
CZ (1) CZ293957B6 (de)
DE (1) DE69621952T2 (de)
DK (1) DK0877750T3 (de)
ES (1) ES2175141T3 (de)
GE (1) GEP20033006B (de)
HK (1) HK1012507A1 (de)
HU (1) HU226822B1 (de)
ID (1) ID16177A (de)
IL (1) IL124268A (de)
MX (1) MX9803447A (de)
MY (1) MY114803A (de)
NO (1) NO311692B1 (de)
NZ (1) NZ321766A (de)
PL (1) PL184698B1 (de)
PT (1) PT877750E (de)
SK (1) SK283552B6 (de)
TW (1) TW448181B (de)
WO (1) WO1997016455A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
NZ525722A (en) * 2000-12-20 2004-11-26 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (de) * 2000-12-20 2005-03-02 Schering Corporation Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
JP4605990B2 (ja) * 2000-12-21 2011-01-05 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な１，２−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
KR20080067717A (ko) * 2001-01-26 2008-07-21 쉐링 코포레이션 스테롤 흡수 억제제와 혈액 조절제를 포함하는 혈관 질환의치료 또는 예방용 약제학적 조성물
SK287746B6 (sk) * 2001-01-26 2011-08-04 Schering Corporation Použitie substituovaných azetidinónových zlúčenín na liečenie sitosterolémie
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
CZ304929B6 (cs) 2001-03-28 2015-01-28 Merck Sharp & Dohme Corp. Enantioselektivní syntéza azetidinonových meziproduktů
DK1429756T3 (da) * 2001-09-21 2007-03-19 Schering Corp Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (de) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Neue hypocholesterolemische Verbindungen
US20070135357A1 (en) * 2003-10-30 2007-06-14 Sings Heather L Anti-hypercholesterolemic compounds
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
WO2006116499A1 (en) * 2005-04-26 2006-11-02 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CA2120221A1 (en) * 1993-04-23 1994-10-24 Allan W. Rey N-substituted 2-azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
BR9612998B1 (pt) 2010-03-23
EP0877750B1 (de) 2002-06-19
NZ321766A (en) 1999-07-29
HUP9802539A2 (hu) 1998-11-30
SK283552B6 (sk) 2003-09-11
SK48398A3 (en) 1998-11-04
NO981950L (no) 1998-06-26
DK0877750T3 (da) 2002-07-15
MX9803447A (es) 1998-09-30
CN1205707A (zh) 1999-01-20
KR19990067202A (ko) 1999-08-16
CN1103780C (zh) 2003-03-26
ATE219495T1 (de) 2002-07-15
DE69621952T2 (de) 2003-01-16
CA2235943A1 (en) 1997-05-09
WO1997016455A1 (en) 1997-05-09
GEP20033006B (en) 2003-07-10
JP2001048895A (ja) 2001-02-20
NO311692B1 (no) 2002-01-07
HU226822B1 (en) 2009-11-30
PL327987A1 (en) 1999-01-04
JP3385031B2 (ja) 2003-03-10
HK1012507A1 (en) 1999-08-06
PL184698B1 (pl) 2002-12-31
BR9611401A (pt) 1999-01-05
ES2175141T3 (es) 2002-11-16
NO981950D0 (no) 1998-04-29
CZ293957B6 (cs) 2004-08-18
KR100311554B1 (ko) 2002-06-20
CA2235943C (en) 2002-10-01
PT877750E (pt) 2002-09-30
DE69621952D1 (de) 2002-07-25
IL124268A (en) 2005-08-31
AU712158B2 (en) 1999-10-28
AR004701A1 (es) 1999-03-10
CZ129498A3 (cs) 1998-10-14
HUP9802539A3 (en) 1999-12-28
BR9611401B1 (pt) 2010-08-10
ID16177A (id) 1997-09-11
AU7517996A (en) 1997-05-22
EP0877750A1 (de) 1998-11-18
MY114803A (en) 2003-01-31
JPH10512592A (ja) 1998-12-02
TW448181B (en) 2001-08-01

Similar Documents

Publication Publication Date Title
CY2353B1 (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents.
ZA9610858B (en) Heteroclyclic compounds.
ZA967315B (en) Biphenylamides.
ZA965934B (en) Chemical compounds.
ZA966610B (en) Chemical compounds.
ZA964715B (en) Raman Microscope.
AU2943095A (en) Substituted azetidinone compounds useful as hypocholesterolemic agents
ZA965505B (en) Novel compounds.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA966245B (en) Examining a diamond.
ZA985875B (en) Azetidines.
ZA962277B (en) Cutting mechanism.
GB9524180D0 (en) Hammer mechanism
ZA966399B (en) Endothelin-receptor-antagonists.
ZA964560B (en) Anit-viral compounds.
ZA966750B (en) Halogenobenzimidazoles.
ZA969089B (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
HUP9600944A3 (en) Automotive window construction
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
AU3427795A (en) Hydraulic reciprocating mechanism
AU6241896A (en) Operation unit
ZA964264B (en) Retinoid-like compounds.
ZA963324B (en) Door.
ZA962091B (en) Diaries.
ZA965504B (en) Novel compounds.